** Shares of Dr. Reddy's Laboratories REDY.NS down 4.5% at 1,232 rupees, top loser on benchmark Nifty 50 .NSEI
** Co misses Q3 FY25 profit misses estimates and warns of drop in key product Lenalidomide's sales in H2 of FY26
** Lenalidomide is a generic of Bristol-Myers's cancer drug Revlimid
** Nuvama says "As gRevlimid is nearing the cliff, investor attention is focused on how DRL offsets the gRevlimid impact on earnings"; adds key product approvals is critical
** Already weak Lenalidomide sales of led to 11% sequential decline in REDY's Q3 North America sales
** Jefferies notes increased competition in North America
** Session's loss trims 12 month stock price gain to 5.07%
(Reporting by Ananta Agarwal in Bengaluru)
((Ananta.Agarwal@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。